Cosmos Health Inc. (COSM) Fair Value & Analysis

Healthcare · US · Market cap $13.2M · ISIN US2214133058

What is Cosmos Health Inc. really worth?

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The large discount to fair value meets weak quality (30/100). That raises the risk this is a value trap rather than a bargain.
• The price is below even our cautious bear case ($0.4806). The market is more pessimistic than our downside scenario.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• A fairly wide model range ($0.4806 to $1.08) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 24, 2026.

How to read this chart

60‑month range $0.0730 – $23.01 · fair‑value band $0.4806 – $1.08 · the $0.2730 price screens below the $0.8190 fair value. Dashed = 300-day average. As of Aug 24, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Cosmos Health Inc. (COSM) currently trades at $0.2730, while our model-based Fair Value estimate is $0.8190, implying the stock looks roughly 66.7% undervalued today. The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector. Bull case: the Dividend Discount group reads highest at a median of $1.10 per share, and 2 of the 3 models we run sit above the $0.2730 price. Bear case: the Asset-Based group reads lowest at $0.2000, and 1 of the 3 models stay below the price. Evidence for this calculation is low.

Over the trailing twelve months, Cosmos Health Inc. generated revenue of $69.5M at a net margin of −30.4%. Revenue grew 30.7% year over year. It earns a return on equity of −92.3%. Net debt stands at $19.3M. Fundamentals as of Aug 24, 2026

Our scenario range runs from $0.4806 (bear case) to $1.08 (bull case); at $0.2730, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 79% below its 52-week high and 49% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at 200%, COSM screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Widest divergence: Dividend Discount ($1.10) versus Asset-Based ($0.2000). Highest evidence: Gordon GGM (66).

Key figures & financial health

Quality Score breakdown

About the company

Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus.

Full company description

Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus. The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It offers ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), Newzypra (Olanzapine), PNEUMO-KAST (Montelukast), Sahar (Pioglitazone), VIVALCID (Leucovorin), and Diabit-is (Sitagliptin). In addition, the company offers branded biocides and antiseptic soaps under the C-Sept and C-Scrub brand names; and other pharmaceutical products include Melatonin Spray, used to reduce insomnia and jet lag; Otikon ear drops, which is a Class II medical device in the form of ear drops; and baby foods, such as organic powder milk, pasta with minced meat, whole grain rice cereals, whole grain cereal porridges, and organic rice creams with vanilla milk, as well as pear, carrot and banana purée under the Bio-bebe brand. It serves wholesalers and retail healthcare providers. The company was founded in 2009 and is headquartered in Thessaloniki, Greece.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Cosmos Health Inc. reported revenue of $65.3M in FY2025 versus $56.2M in FY2021, a compound +3.8%/yr. Reported net income was −$19.1M in FY2025.

Watch COSM: get an alert when its fair value changes →

Peer Group

Medical Distribution · 79 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Medical Distribution median · lower = cheaper

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Aug 24, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions